Diferencia entre revisiones de «Template:Cholecystitis Antibiotics»

(Convert to {{AntibioticDose}} for SMW antibiotic-disease linking)
(Add disease=Cholecystitis parameter to AntibioticDose calls - fixes aggregation page display issue)
Línea 3: Línea 3:
====Uncomplicated====
====Uncomplicated====
''Pathogenicity of [[Enterococci]] remains unclear and specific coverage is not routinely suggested for community-acquired infections''<ref name="WSES 2016">Ansaloni L, et al. 2016 WSES guidelines on acute calculous cholecystitis. World Journal of Surgery. (2016) 11:25. DOI 10.1186/s13017-016-0082-5</ref>
''Pathogenicity of [[Enterococci]] remains unclear and specific coverage is not routinely suggested for community-acquired infections''<ref name="WSES 2016">Ansaloni L, et al. 2016 WSES guidelines on acute calculous cholecystitis. World Journal of Surgery. (2016) 11:25. DOI 10.1186/s13017-016-0082-5</ref>
*{{AntibioticDose|drug=Ertapenem|dose=1g IV once daily|context=Uncomplicated}} OR
*{{AntibioticDose|disease=Cholecystitis|drug=Ertapenem|dose=1g IV once daily|context=Uncomplicated}} OR
*{{AntibioticDose|drug=Metronidazole|dose=500mg IV q8hrs|context=Uncomplicated}} PLUS
*{{AntibioticDose|disease=Cholecystitis|drug=Metronidazole|dose=500mg IV q8hrs|context=Uncomplicated}} PLUS
**{{AntibioticDose|drug=Ciprofloxacin|dose=400mg IV q12 hrs|context=Uncomplicated}} OR
**{{AntibioticDose|disease=Cholecystitis|drug=Ciprofloxacin|dose=400mg IV q12 hrs|context=Uncomplicated}} OR
**{{AntibioticDose|drug=Levofloxacin|dose=750mg IV q24hrs|context=Uncomplicated}} OR
**{{AntibioticDose|disease=Cholecystitis|drug=Levofloxacin|dose=750mg IV q24hrs|context=Uncomplicated}} OR
**{{AntibioticDose|drug=Ceftriaxone|dose=1g IV q24hrs|context=Uncomplicated}}
**{{AntibioticDose|disease=Cholecystitis|drug=Ceftriaxone|dose=1g IV q24hrs|context=Uncomplicated}}


====Complicated or Healthcare Associated====
====Complicated or Healthcare Associated====
''Examples of complication include severe [[sepsis]] or hemodynamic instability''
''Examples of complication include severe [[sepsis]] or hemodynamic instability''
*{{AntibioticDose|drug=Vancomycin|dose=15-20mg/kg|context=Complicated/Healthcare Associated}} PLUS any of the following options
*{{AntibioticDose|disease=Cholecystitis|drug=Vancomycin|dose=15-20mg/kg|context=Complicated/Healthcare Associated}} PLUS any of the following options


'''Options:'''
'''Options:'''
*{{AntibioticDose|drug=Metronidazole|dose=500mg IV q8hrs|context=Complicated}} PLUS {{AntibioticDose|drug=Ciprofloxacin|dose=400mg IV q12hrs|context=Complicated}}
*{{AntibioticDose|disease=Cholecystitis|drug=Metronidazole|dose=500mg IV q8hrs|context=Complicated}} PLUS {{AntibioticDose|disease=Cholecystitis|drug=Ciprofloxacin|dose=400mg IV q12hrs|context=Complicated}}
*{{AntibioticDose|drug=Piperacillin/Tazobactam|dose=4.5g IV q8hrs|context=Complicated}}
*{{AntibioticDose|disease=Cholecystitis|drug=Piperacillin/Tazobactam|dose=4.5g IV q8hrs|context=Complicated}}
*{{AntibioticDose|drug=Imipenem/Cilastatin|dose=500mg IV q6hrs|context=Complicated}}
*{{AntibioticDose|disease=Cholecystitis|drug=Imipenem/Cilastatin|dose=500mg IV q6hrs|context=Complicated}}
*{{AntibioticDose|drug=Doripenem|dose=500mg IV q8hrs|context=Complicated}}
*{{AntibioticDose|disease=Cholecystitis|drug=Doripenem|dose=500mg IV q8hrs|context=Complicated}}
*{{AntibioticDose|drug=Meropenem|dose=1g IV q8hrs|context=Complicated}}
*{{AntibioticDose|disease=Cholecystitis|drug=Meropenem|dose=1g IV q8hrs|context=Complicated}}

Revisión del 23:12 19 mar 2026

Most often isolated organisms are Escherichia coli, Klebsiella pneumonia, and anaerobes, especially Bacteroides fragilis

Uncomplicated

Pathogenicity of Enterococci remains unclear and specific coverage is not routinely suggested for community-acquired infections[1]

Complicated or Healthcare Associated

Examples of complication include severe sepsis or hemodynamic instability

  • Vancomycin 15-20mg/kg PLUS any of the following options

Options:

  1. Ansaloni L, et al. 2016 WSES guidelines on acute calculous cholecystitis. World Journal of Surgery. (2016) 11:25. DOI 10.1186/s13017-016-0082-5